Neurotech International Ltd. · ASX:NTI
Neurotech International — Shareholder Meeting (November 2025)
23 slides from Neurotech International's shareholder meeting presentation, Nov 20, 2025
Slide 1: Advancing Neuroscience Transforming Lives
For personal use only Advancing Neuroscience Transforming Lives Dr Anthony Filippis Chief Executive Officer & Managing Director Presentation 0 to 2025 Annual General Meeting Melbourne, VIC 20 November 2025
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes forward looking statements. Forward looking statements can generally be identified by the use of the words “anticipate”, “believe”, “expect”, “project”, “forecast”, “estimate”, “likely”, “intend”, “should”, “could”, “may”, “target”, “plan” “guida
Slide 3: Year in review
Year in review Key progress in CY2025 to drive growth in CY2026 For personal use only Regulatory progress in US and Europe February 2025 • Positive opinion on OMPD for NTI164 in Europe March 2025 • European Commission grants NTI164 Orphan Drug Designation for Rett syndrome October 2025 • US FDA Rare
Slide 4: Targeting high impact indications where there is a clear unmet market need
Targeting high impact indications where there is a clear unmet market need autism spectrum disorder (ASD) • High unmet need for safe, effective For personal use only treatments for core symptoms • 1 in 31 children (US) • Current market ~US$3B[2] and growing • Boys 4x more likely to be diagnosed • Gr
Slide 5: Neurotech's pipeline comprises clinical programs in neurodevelopmental disorders of children
Neurotech’s pipeline comprises clinical programs in neurodevelopmental disorders of children where neuroinflammation is involved For personal use only NTI164 Targets neuroinflammation PRECLIN. PHASE 1 PHASE 2 PHASE 3 MARKET Neurodevelopmental disorders PI: Phase I/II data Autism Spectrum Disorder Pr
Slide 6: What is NTI164?
What is NTI164? For personal use only ❶ Disease-modifying and transformative therapy ❼ Safe and effective in non-clinical and in paediatric neurodevelopmental disorders clinical studies ❷ Full-spectrum, low-THC (<0.3%) ❻ Patents cover composition of matter, cannabinoid formulation methods of use and
Slide 7: NTI164's mechanism of action is to reduce neuroinflammation
NTI164’s mechanism of action is to reduce neuroinflammation Inflammatory cytokines are down-regulated by NTI164 in in vitro models For personal use only Cytokine % reduction iNOS 38% COX2 62% TNF-⍺ 72% IL-5 32% IL-1β 47% TGF-β 27% NTI164 works on core neurological mechanisms: • reduces neuroinflamma
Slide 8: NTI164: Robust non-clinical safety and pharmacology profile
NTI164: Robust non-clinical safety and pharmacology profile Non-clinical data summary Significance of non-clinical data For personal use only Category Key Findings Category Key Insights Full-spectrum Cannabis sativa extract, Meets non-clinical safety standards for Source & Composition <0.3% THC, ric
Slide 9: NTI164 has shown compelling evidence of clinical efficacy
NTI164 has shown compelling evidence of clinical efficacy Up titration over 4 weeks starting at 5mg/kg/day up to 20mg/kg/day MTD For personal use only ASD HARMONY Phase 2/3 CGI-I Total Score+ Rett Syndrome Phase 1/2 CGI-I Total Score^# PANS Phase 1/2 CGI-I Total Score# Clinical trial results ASD Ret
Slide 10: Impressive data-points across all indications
Impressive data-points across all indications Clinical Trial data For personal use only Statistical Indication Key Outcome Measures Results Duration Safety Significance No serious AEs; mild GI complaints in ASD[1] Vineland-3 ↑ 3.23 points (clinically meaningful) p = 0.024 8 weeks few cases Excellent
Slide 11: Clinical Trial data – Autism Spectrum Disorder Phase II/III (The HARMONY Study)
Clinical Trial data – Autism Spectrum Disorder Phase II/III (The HARMONY Study) Statistical Assessment Subdomain Results Duration Safety Significance Total score (Adaptive behaviour composite) p = 0.024 For personal use only ↑ 3.23 points (clinically meaningful Communication (ability to understand a
Slide 12: Pivot company towards regulatory & commercialisation path to grow shareholder value
Pivot company towards regulatory & commercialisation path to grow shareholder value For personal use only Autism spectrum disorder Authorised Prescriber program TGA IND submission Rett syndrome Authorised Prescriber program TGA Orphan Drug Designation Rare Paediatric Disease Designation IND submissi
Slide 13: Authorised Prescriber (AP): Enabling NTI164 demand
Authorised Prescriber (AP): Enabling NTI164 demand • Commercial access and registration strategy For personal use only • Rationale for AP program was due to demand for NTI164 • Scalable access through NTI-selected Australian registered medical practitioners under supervised environment • Authorised
Slide 14: First Phase III registration clinical trial in ASD has been designed
PRELIMINARY First Phase III registration clinical trial in ASD has been designed use only Patient Population: Placebo n = 75* Follow-Up RANDOMISATION Blinded Treatment For personal SCREENING • ASD Level II or III Period Open-Label Extension • Total 24-week • 5 – 17 years of age Period duration • Sta
Slide 15: The competitive landscape is not crowded with few approved therapies
The competitive landscape is not crowded with few approved therapies Early Development Late Development Approved Risperdal firstly developed by For personal use only Autism Spectrum Disorder NTI164 Janssen-Cilag & Ablify by Otsuka Several off-label use of other neuropsychiatric drugs which Originall
Slide 16: Market comparators provide a strong precedent for NTI164
AS AT 03 OCT 2025 Market comparators provide a strong precedent for NTI164 Market comparators Company Comparable pipeline Market Cap For personal use only (cannabidiol, approved) ~ US$8.5B (approved) ~ US$3.7B NNZ-2591 Phase 2 data including Angelman, Phelan McDermid, Pitt Hopkins ~AU$2.7B Anavex 2-
Slide 17: Broad outreach program to socialise and nurture potential future partners
The company has commenced a broad outreach program to socialise and nurture potential future partners for NTI164 Benchmarks for Phase II/III Neuro Disease Partnering For personal use only Typical Structure of Pharma Partnering Transactions Transactions (2016 – 2025 YTD) (n=64) Low Median High Upfron
Slide 18: Partnering opportunity for NTI164 is substantial
Partnering opportunity for NTI164 is substantial, with benchmark transactions suggesting significant value potential Licensing Transactions Licensee Licensor Key Asset(s) Key Indication(s) Stage Date Deal Value (US$) For personal use only PTC518 Huntington’s disease Phase II Nov 2024 $2.9B ABV-1504/
Slide 19: Bringing botanical medicines to market: it can be done
Bringing botanical medicines to market: it can be done FDA-approved botanical prescription drugs For personal use only Active FDA Drug name Botanical source Indication(s) Notes ingredient(s) approval Camellia sinesis (green First FDA approved botanical ointment; standardised Veregen® Sinecatechins G
Slide 20: Neurotech Board and management bring extensive international experience
Neurotech Board and management bring extensive international experience in drug development, finance and commercialisation For personal use only Mr Mark Davies Dr Anthony Filippis Mr Max Johnston Board Chair Managing Director & CEO Non-Executive Director Over 25 years Over 25 years of life Over 40 y
Slide 21: Neurotech financial position and value drivers
AS AT 03 OCT 2025 Neurotech financial position and value drivers Corporate Fundamentals For personal use only Market Capitalisation: ~AU$ 20M Primary Listing: ASX: NTI Huge Market Potential Shares on Issue: 1.05 Billion Addressing high-growth neurological markets Proven science and de-risked program
Slide 22: Value-driving catalysts on the horizon
Value-driving catalysts on the horizon For personal use only CY2026 Human Research Ethics Committee approval for ASD registration-enabling study 1Q CY2026 Initiation of clinical sites 1Q CY2026 First patient enrolled in ASD clinical trial Mid CY2026 Long-term chronic toxicology data Mid CY2026 IND s
Slide 23: Contact Details
For personal use only Contact Details Neurotech Investor Relations info@neurotechinternational.com This presentation has been authorised by the Board of Neurotech International Limited www.neurotechinternational.com Neurotech International Limited (ASX: NTI) 22
Neurotech International — Shareholder Meeting (November 2025) on 6ix